Multi-label diagnostic classification on MS-CXR-T
77.7Consolidation ScoreCPO
Evaluation results
| Method | Links | ||||||
|---|---|---|---|---|---|---|---|
| CPOVenue=NeurIPS’252026.04 | 77.7 | 72.7 | 87.4 | 95.8 | 75.3 | 81.8 | |
| CPO++2026.04 | 77 | 78.1 | 87.6 | 95.4 | 78.4 | 83.3 | |
| XrayClawCategory=Multi-Agent2026.04 | 73.9 | 74.9 | 72.7 | 88.7 | 79.3 | 77.9 | |
| RadFabricVenue=Arxiv‘25, Category=Multi-Agent2026.04 | 73.7 | 45 | 73.3 | 85 | 66.7 | 68.7 | |
| CoCa-CXRVenue=MICCAI’25, Category=MLLMs-Based2026.04 | 70.4 | 69.6 | 61.4 | 72.8 | 71.8 | 69.2 | |
| CoCa-CXRVenue=MICCAI’252026.04 | 70.4 | 69.6 | 61.4 | 72.8 | 71.8 | 69.2 | |
| MedRAXVenue=ICML’25, Category=Multi-Agent2026.04 | 69.3 | 76.5 | 62.7 | 83.6 | 73.2 | 73.1 | |
| TempA-VLPVenue=WACV’25, Category=MLLMs-Based2026.04 | 65.2 | 59.4 | 73.4 | 43.1 | 77.1 | 63.6 | |
| TempA-VLPVenue=WACV’252026.04 | 65.2 | 59.4 | 73.4 | 43.1 | 77.1 | 63.6 | |
| DPOVenue=NeurIPS’232026.04 | 63.2 | 72.4 | 76.7 | 93.5 | 76.3 | 76.4 | |
| BioViL-TVenue=CVPR’23, Category=MLLMs-Based2026.04 | 61.1 | 67 | 61.9 | 42.6 | 68.5 | 60.2 | |
| BioViL-TVenue=CVPR’232026.04 | 61.1 | 67 | 61.9 | 42.6 | 68.5 | 60.2 | |
| Med-STVenue=ICML’24, Category=MLLMs-Based2026.04 | 60.6 | 67.4 | 58.5 | 65 | 54.2 | 61.1 | |
| Med-STVenue=ICML’242026.04 | 60.6 | 67.4 | 58.5 | 65 | 54.2 | 61.1 | |
| BioViLVenue=ECCV’22, Category=MLLMs-Based2026.04 | 56 | 63 | 60.2 | 42.5 | 67.5 | 57.8 | |
| BioViLVenue=ECCV’222026.04 | 56 | 63 | 60.2 | 42.5 | 67.5 | 57.8 | |
| SFT2026.04 | 54.9 | 71.7 | 70 | 95.9 | 76.5 | 73.8 | |
| CheXRelNetVenue=MICCAI’22, Category=MLLMs-Based2026.04 | 47 | 47 | 47 | 36 | 49 | 45.2 | |
| CheXRelNetVenue=MICCAI’222026.04 | 47 | 47 | 47 | 36 | 49 | 45.2 | |
| CTransformerVenue=CVPR’23, Category=MLLMs-Based2026.04 | 44 | 61.3 | 45.1 | 31.5 | 65.5 | 49.5 | |
| CTransVenue=CVPR’232026.04 | 44 | 61.3 | 45.1 | 31.5 | 65.5 | 49.5 |